

## Instructions to Authors 2013

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios  
 International Institute of Anticancer Research (IIAR)  
 Editorial Office of ANTICANCER RESEARCH,  
 IN VIVO, CANCER GENOMICS and PROTEOMICS.  
 1st km Kapandritiou-Kalamou Road  
 P.O. Box 22, GR-19014 Kapandriti, Attiki  
 GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study). R. LÓPEZ, C. MÉNDEZ MÉNDEZ, M. JORGE FERNÁNDEZ, C. ROMERO REINOSO, G. QUINTERO ALDANA, M. SALGADO FERNÁNDEZ, J. DE LA CÁMARA GÓMEZ, M. REBOREDO LÓPEZ, M. RAMOS VÁZQUEZ, S. CANDAMIO FOLGAR ( <i>Santiago de Compostela; A Coruña; Vigo; Lugo; Ourense, Spain</i> ) .....	717
Long-term Results of Preoperative 5-Fluorouracil-Oxaliplatin Chemoradiation Therapy in Locally Advanced Rectal Cancer. E. FONTANA, F. PUCCI, R. CAMISA, S. BUI, S. GALDY, F. LEONARDI, F.V. NEGRI, E. ANSEMI, P.L. LOSARDO, L. RONCORONI, P. DELL'ABATE, P. CRAFA, S. CASCINU, A. ARDIZZONI ( <i>Parma; Bergamo; Piacenza; Ancona, Italy</i> ) .....	725
Lumpectomy <i>versus</i> Mastopexy – A Post-surgery Patient Survey. C. EICHLER, M. KOLSCH, A. SAUERWALD, A. BACH, O. GLUZ, M. WARM ( <i>Cologne; Düren; Eschweiler; Moenchengladbach, Germany</i> ) .....	731
Screening of Circulating TGF- $\beta$ Levels and Its Clinicopathological Significance in Human Breast Cancer. C. PANIS, A.C. HERRERA, V.J. VICTORINO, A.M.F. ARANOME, R. CECCHINI ( <i>Londrina, Paraná, Brazil</i> ) .....	737
Errata .....	743
Retraction .....	744
Book Reviews .....	745

Sun Exposure Habits and Health Risk-related Behaviours Among Individuals with Previous History of Skin Cancer. M. FALK, Å. FARESJÖ, T. FARESJÖ ( <i>Linköping, Sweden</i> ) .....	631
Double Inv(3)(q21q26), a Rare but Recurrent Chromosomal Abnormality in Myeloid Hemopathies. E. DE BRAEKELEER, N. DOUET-GUILBERT, M.-J. LE BRIS, J.-C. IANOTTO, C. BERTHOU, N. GUEGANIC, C. BOVO, A. BASINKO, F. MOREL, M. DE BRAEKELEER ( <i>Brest, France</i> ) .....	639
Feasibility Trial for Daily Oral Administration of the Hypoxic Sensitizer AK-2123 (Sanazole) in Radiotherapy. H. YAMAZAKI, S. NAKAMURA, K. KOBAYASHI, T. TSUBOKURA, N. KODANI, N. AIBE, K. YOSHIDA, T. KAGIYA, M. KOIZUMI, K. YAMADA ( <i>Kyoto; Osaka, Japan</i> ) .....	643
Immunoexpression of DIABLO, AIF and Cytochrome c in Gastric Adenocarcinoma Assessed by Tissue Microarray. L.C. DA SILVA, N.M. FORONES, D.A. RIBEIRO, S.S. IHARA, T.S. GOMES, R.A. NETO, C.T. OSHIMA ( <i>São Paulo, SP, Brazil</i> ) .....	647
Ablative or Palliative Stereotactic Body Radiotherapy with Helical Tomotherapy for Primary or Metastatic Lung Tumor. M. MARCENARO, S. VAGGE, L. BELGIOIA, D. AGNESE, G. LAMANNA, E. MANTERO, M. GUSINU, S. GARELLI, F. CAVAGNETTO, S. AGOSTINELLI, R. CORVÒ ( <i>Genoa, Italy</i> ) .....	655
Levels of Sirolimus in Saliva vs. Blood – the Rationale of Topical Oral Use for Oral Malignancy. Z. NUDELMAN, N. KESHET, M. DRANITZKI ELHALAL, M. FRIEDMAN, R. CZERNINSKI ( <i>Jerusalem, Israel</i> ) .....	661
A Method to Assess the Distribution and Frequency of Plasma Cells and Plasma Cell Precursors in Autoimmune Hepatitis. C.A. RUBIO, K. TRUSKAITE, R. RAJANI, A. KAUFELDT, M.-L. LINDSTRÖM ( <i>Stockholm, Sweden</i> ) .....	665
The Contribution of <i>Caveolin-1</i> Genotype and Phenotype to Hepatocellular Carcinoma. C.-M. HSU, M.-D. YANG, C.-W. TSAI, C.-Y. HO, W.-S. CHANG, S.-C. CHANG, L.-B. JENG, Y. TSAI, F.-J. TSAI, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ) .....	671
Lenograstim in Preventing Chemotherapy-induced Febrile Neutropenia in Patients with Soft Tissue Sarcoma. G. BADALAMENTI, L. INCORVAIA, S. PROVENZANO, G. BRONTE, G. LETO, F. FULFARO, G. MALTESE ( <i>Palermo, Italy</i> ) .....	679
Adenocarcinoma Associated with Perianal Fistulas in Crohn's Disease. H. OGAWA, S. HANEDA, C. SHIBATA, K. MIURA, M. NAGAO, S. OHNUMA, A. KOHYAMA, M. UNNO ( <i>Sendai, Japan</i> ) .....	685
Antioxidant Effects of Potassium Ascorbate with Ribose in Costello Syndrome. C. ANICHINI, F. LOTTI, A. PIETRINI, C. LO RIZZO, M. LONGINI, F. PROIETTI, C. FELICI, G. BUONOCORE ( <i>Siena, Italy</i> ) .....	691
Biweekly Docetaxel and S-1 Combination Chemotherapy as First-line Treatment for Elderly Patients with Advanced Gastric Cancer. C. KUNISAKI, M. TAKAHASHI, H.A. ONO, S. HASEGAWA, K. TSUCHIDA, T. OSHIMA, M. OTA, T. FUKUSHIMA, M. TOKUHISA, Y. IZUMISAWA, R. TAKAGAWA, J. KIMURA, T. KOSAKA, H. MAKINO, H. AKIYAMA, I. ENDO ( <i>Yokohama, Japan</i> ) .....	697
Postoperative Peak Serum C-Reactive Protein Predicts Outcome of Hepatic Resection for Hepatocellular Carcinoma. H. SHIBA, K. FURUKAWA, Y. FUJIWARA, Y. FUTAGAWA, K. HARUKI, S. WAKIYAMA, Y. ISHIDA, T. MISAWA, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	705
Abnormal Cytology during Pregnancy – A Retrospective Analysis of Patients in a Dysplasia Clinic. M. HENES, F. NEIS, K. RALL, T. IFTNER, A. STAEBLER, T. FEHM, R. ROTHMUND ( <i>Tuebingen, Germany</i> ) .....	711

The Contribution of <i>XRCC6/Ku70</i> to Hepatocellular Carcinoma in Taiwan. C.-M. HSU, M.-D. YANG, W.-S. CHANG, L.-B. JENG, M.-H. LEE, M.-C. LU, S.-C. CHANG, C.-W. TSAI, Y. TSAI, F.-J. TSAI, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ).....	529
COX-2 Overexpression Induced by Gene Transfer Reduces Sensitivity of TE13 Esophageal Carcinoma Cells to 5-Fluorouracil and Cisplatin. H. OKAMURA, H. FUJIWARA, S. UMEHARA, S. OKAMURA, M. TODO, A. FURUTANI, M. YONEDA, A. SHIOZAKI, S. KOMATSU, T. KUBOTA, D. ICHIKAWA, K. OKAMOTO, T. OCHIAI, C. SAKAKURA, Y. TAKAHASHI, T. YOSHIMOTO, E. OTSUJI ( <i>Kyoto; Okayama; Kanazawa, Japan</i> ) .....	537
<i>Clinical Studies</i>	
Sunlight, Polymorphisms of Vitamin D-related Genes and Risk of Breast Cancer. B.J. FUHRMAN, D.M. FREEDMAN, P. BHATTI, M.M. DOODY, Y.-P. FU, S.-C. CHANG, M.S. LINET, A.J. SIGURDSON ( <i>Bethesda; Gaithersburg, MD; Seattle, WA; San Francisco, CA, USA</i> ) .....	543
Predicting Prostate Biopsy Outcome Using a PCA3-based Nomogram in a Polish Cohort. M. SALAGIERSKI, P. MULDER, J.A. SCHALKEN ( <i>Łódź, Poland; Nijmegen, Netherlands</i> ) .....	553
Prognosis of Rectal Carcinoma after Multimodal Treatment: ypTNM Classification and Tumor Regression Grading Are Essential. P. HERMANEK, S. MERKEL, W. HOHENBERGER ( <i>Erlangen, Germany</i> ) .....	559
Pancreatic Resection for Metastatic Melanoma Originating from the Nasal Cavity: A Case Report and Literature Review. M. SUGIMOTO, N. GOTOHDA, Y. KATO, S. TAKAHASHI, T. KINOSHITA, H. SHIBASAKI, M. KOJIMA, A. OCHIAI, S. ZENDA, T. AKIMOTO, M. KONISHI ( <i>Kashiwa, Chiba, Japan</i> ).....	567
Expression of Hepatocyte Growth Factor Activator Inhibitor Type-1 (HAI-1) in Prostate Cancer. K. YASUDA, A. KOMIYA, A. WATANABE, A. MORII, T. OYA, O. NAGAKAWA, Y. FUJIIUCHI, H. FUSE ( <i>Toyama, Toyama; Jyoutsu-shi, Niigata, Japan</i> ) .....	575
Perineural Invasion and Preoperative Serum CA19-9 as Predictors of Survival in Biliary Tract Cancer. H. KAWAMATA, K. YAMASHITA, K. NAKAMURA, H. KATAGIRI, K. ISHII, Y. TAKAHASHI, K. FURUTA, Y. KUMAMOTO, M. WATANABE ( <i>Kanagawa, Japan</i> ) .....	583
Long-term Survival of Advanced Small Cell Carcinoma of the Esophagus after Resection: A Case Report. K. MUGURUMA, M. OHIRA, H. TANAKA, N. KUBO, Y. YAMASHITA, T. SAWADA, K. WAKASA, K. HIRAKAWA ( <i>Osaka, Japan</i> ) .....	595
Clinical Outcomes and Prognosis after Thoracoscopic Esophagectomy with Two-field Lymph Node Dissection for Lower Thoracic Esophageal Cancer. M. TAKEMURA, T. HORI, Y. FUJIWARA ( <i>Hyogo; Osaka, Japan</i> ) .....	601
Correlation of Aquaporin-1 Water Channel Protein Expression with Tumor Angiogenesis in Human Astrocytoma. N. EL HINDY, A. BANKFALVI, A. HERRING, M. ADAMZIK, N. LAMBERTZ, Y. ZHU, W. SIFFERT, U. SURE, I.E. SANDALCIOGLU ( <i>Essen, Germany</i> ) .....	609
Primary Vesical Clear Cell Adenocarcinoma Arising in Endometriosis: A Rare Case of Mullerian Origin. K. LAH, D. DESAI, P. HADWAY, J. PERRY-KEENE, G. COUGHLIN ( <i>Herston, QLD, Australia</i> ) .....	615
Endometrial Carcinoma in the Baby Boomer Generation. Tumor Characteristics and Clinical Outcome. M.A. ELSHAIKH, R. CATTANEO II, M. SHAH, S. PATEL, M. MAHAN, T. BUEKERS, F. SIDDIQUI ( <i>Detroit, MI, USA</i> ) .....	619
Practical Utility of Circulating Tumour Cells as Biomarkers in Cancer Chemotherapy for Advanced Colorectal Cancer. K. OTSUKA, H. IMAI, H. SOEDA, K. KOMINE, C. ISHIOKA, H. SHIBATA ( <i>Akita; Sendai, Japan</i> ) .....	625

Regulation of the Proliferation of Colon Cancer Cells by Compounds that Affect Glycolysis, Including 3-Bromopyruvate, 2-Deoxyglucose and Biguanides. M.A. LEA, M.S. QURESHI, M. BUXHOEVEDEN, N. GENDEL, J. KLEINSCHMIT, C. desBORDES ( <i>Newark, NJ; Brooklyn, NY, USA</i> ) .....	401
VEGF-C ShRNA Inhibits Pancreatic Cancer Growth and Lymphangiogenesis in an Orthotopic Fluorescent Nude Mouse Model. Y. SHI, M. TONG, Y. WU, Z. YANG, R.M. HOFFMAN, Y. ZHANG, Y. TIAN, M. QI, Y. LIN, Y. LIU, L. DAI, Y. SUN, Z. WANG ( <i>Shanghai; Jiangsu; Chongqing, PR China; San Diego, CA, USA</i> ) .....	409
Intraoperative Imaging of Metastatic Lymph Nodes Using a Fluorophore-conjugated Antibody in an Orthotopic Breast Cancer Mouse Model of HER2/neu. J. WU, R. MA, H. CAO, Z. WANG, C. JING, Y. SUN, Y. ZHANG, Z. YANG, R.M. HOFFMAN, J. TANG ( <i>Jiangsu, PR China; San Diego, CA, USA</i> ) ....	419
Azatyrosinamides: Novel RAS-related Anticancer Agents. C.-L. WANG, O. LEE, C.-F. HUANG, E.I-C. LI, C.-M. TENG, S.-L. PAN, J.-F. LIAN, F.-S. CHANG, J.-P. LIOU, H.-P. WANG ( <i>Taipei; Hsinchu City; Tainan; Miaoli County, Taiwan, ROC</i> ) .....	425
Combined Colonic Cancer Treatment with Vitamin D Analogs and Irinotecan or Oxaliplatin. M. MILCZAREK, S. ROSIŃSKA, M. PSURSKI, M. MACIEJEWSKA, A. KUTNER, J. WIETRZYK ( <i>Wroclaw; Warsaw; Czestochowa, Poland</i> ).....	433
MicroRNA 181a Influences the Expression of HMGB1 and CD4 in Acute Leukemias. M. DAHLHAUS, C. SCHULT, S. LANGE, M. FREUND, C. JUNGHANSS ( <i>Rostock, Germany</i> ) .....	445
New Biological Activities of Rhinacanthins from the Root of <i>Rhinacanthus nasutus</i> . H. HORII, R. SUZUKI, H. SAKAGAMI, M. TOMOMURA, A. TOMOMURA, Y. SHIRATAKI ( <i>Sakado, Saitama, Japan</i> ).....	453
Anti-phosphohistone H3 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma. S. NAKASHIMA, A. SHIOZAKI, D. ICHIKAWA, S. KOMATSU, H. KONISHI, D. IITAKA, T. KUBOTA, H. FUJIWARA, K. OKAMOTO, M. KISHIMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	461
Gene Amplification of Ribosomal Protein S6 Kinase-1 and -2 in Gastric Cancer. S. YOSHIDA, K. MATSUMOTO, T. ARAO, H. TANIGUCHI, I. GOTO, T. HANAFUSA, K. NISHIO, Y. YAMADA ( <i>Osaka; Tokyo, Japan</i> ).....	469
Effect of Different Degrees of Hydrogenated Fish Oil on Intestinal Carcinogenesis in <i>Min/+</i> mice. M. MOLIN, P. BERSTAD, J.Š. BENTH, J. ALEXANDER, J.E. PAULSEN, K. ALMENDINGEN ( <i>Oslo; Lørenskog; Aas, Norway</i> ) .....	477
Kinase Activity of Protein Kinase C $\alpha$ in Serum as a Diagnostic Biomarker of Human Lung Cancer. J.-H. KANG, T. MORI, H. KITAZAKI, T. NIIDOME, K. TAKAYAMA, Y. NAKANISHI, Y. KATAYAMA ( <i>Fukuoka, Japan</i> ).....	485
Proteomic Profiling of Trastuzumab (Herceptin <sup>®</sup> )-sensitive and -resistant SKBR-3 Breast Cancer Cells. G. DI CARA, G. MARENCO, N.N. ALBANESE, M.R. MARABETI, R. MUSSO, P. CANCEMI, I. PUCCI-MINAFRA ( <i>Palermo, Italy</i> ) .....	489
Ecteinascidin 770, a Tetrahydroisoquinoline Alkaloid, Sensitizes Human Lung Cancer Cells to Anoikis. P. POWAN, N. SAITO, K. SUWANBORIRUX, P. CHANVORACHOTE ( <i>Bangkok, Thailand; Tokyo, Japan</i> ) ....	505
Functional Polymorphism in the MicroRNA-367 Binding Site as a Prognostic Factor for Colonic Cancer. Y.S. CHAE, J.G. KIM, B.W. KANG, S.J. LEE, Y.J. LEE, J.S. PARK, G.S. CHOI, W.K. LEE, H.-S. JEON ( <i>Daegu, South Korea</i> ).....	513
Pharmacokinetic Drug Interactions between Ondansetron and Tamoxifen in Female Sprague-Dawley Rats with DMBA-induced Mammary Tumor. S.H. YANG, J.H. SUH, M.G. LEE, S.H. KIM ( <i>Seoul; Bucheon; Suwon, South Korea</i> ) .....	521